{"id":180789,"date":"2026-02-13T12:55:26","date_gmt":"2026-02-13T17:55:26","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180789"},"modified":"2026-02-13T12:55:26","modified_gmt":"2026-02-13T17:55:26","slug":"eris-lifesciences-reports-record-quarterly-revenue-of-%e2%82%b9807-crores","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/eris-lifesciences-reports-record-quarterly-revenue-of-%e2%82%b9807-crores\/","title":{"rendered":"Eris Lifesciences Reports Record Quarterly Revenue of \u20b9807 Crores"},"content":{"rendered":"\n

Eris Lifesciences Limited (NSE: ERIS; BSE: 540596)<\/strong> shares closed 6.36% lower at \u20b91,414.65 on Friday despite reporting record quarterly revenues for the period ended December 31, 2025.<\/p>\n\n\n\n

Market Capitalization<\/h2>\n\n\n\n

The market capitalization for Eris Lifesciences stands at approximately \u20b919,584 crores as of the latest close.<\/p>\n\n\n\n

Latest Quarterly Results<\/h2>\n\n\n\n

The company reported consolidated revenue of \u20b9807.45 crores, up 11% year-on-year. Net profit for the quarter rose 25% to \u20b9108.83 crores compared to \u20b987.06 crores in Q3 FY25.<\/p>\n\n\n\n

Segment Highlights:<\/strong><\/p>\n\n\n\n

    \n
  • Branded Formulations:<\/strong> Revenue grew 10% YoY to \u20b9696 crores with 36.5% EBITDA margins.<\/li>\n\n\n\n
  • International:<\/strong> Revenue surged 45% to \u20b9111 crores, marking the strongest quarter for the segment.<\/li>\n\n\n\n
  • Insulin:<\/strong> Market share in Recombinant Human Insulin reached 25%.<\/li>\n<\/ul>\n\n\n\n

    Full Year Results Context<\/h2>\n\n\n\n

    For the nine months ended December 31, 2025, revenue increased to \u20b92,372.86 crores. Net profit grew 35% year-on-year to \u20b9368.40 crores.<\/p>\n\n\n\n

    Financial Trends<\/h2>\n\n\n\n
    \"\"<\/figure>\n\n\n\n
    \"\"<\/figure>\n\n\n\n

    Business & Operations Update<\/h2>\n\n\n\n

    Eris recorded an exceptional item of \u20b917.24 crores due to new labor code implementations. Net debt as of December 31, 2025, was reported at \u20b92,270 crores.<\/p>\n\n\n\n

    M&A or Strategic Moves<\/h2>\n\n\n\n

    On January 16, 2026, Eris completed the acquisition of the remaining 30% stake in Swiss Parenterals Limited, making it a wholly owned subsidiary.<\/p>\n\n\n\n

    Equity Analyst Commentary<\/h2>\n\n\n\n

    Motilal Oswal and PL Capital track the stock. Analysts noted the insulin market share gains but expressed concerns regarding the pace of debt reduction.<\/p>\n\n\n\n

    Guidance & Outlook<\/h2>\n\n\n\n

    Management projects FY26 revenue of \u20b93,200 crores; breakout performance is expected from the international business in FY27.<\/p>\n\n\n\n

    Performance Summary<\/h2>\n\n\n\n

    Eris shares closed at \u20b91,414.65. Revenue grew 11% to a record \u20b9807.45 crores, while 9M profit rose 35%. Exceptional items impacted the quarterly bottom line.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Eris Lifesciences Limited (NSE: ERIS; BSE: 540596) shares closed 6.36% lower at \u20b91,414.65 on Friday despite reporting record quarterly revenues for the period ended December 31, 2025. Market Capitalization The market capitalization for Eris Lifesciences stands at approximately \u20b919,584 crores as of the latest close. Latest Quarterly Results The company reported consolidated revenue of \u20b9807.45 […]<\/p>\n","protected":false},"author":2400,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747],"tags":[13743,16506],"class_list":["post-180789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-health-care","tag-health-care-facilities-services"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":166104,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q2fy25-21-fall-in-profits\/","url_meta":{"origin":180789,"position":0},"title":"ERIS Lifesciences Ltd Q2FY25; 21% fall in Profits","author":"Divyansh_Kasana","date":"December 18, 2024","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q2FY25 of \u20b9741.00 Crores up from \u20b9505.00 Crore year on year, a rise of 46.73%. Total Expenses for Q2FY25 of \u20b9616.00 Crores up from \u20b9382.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/PP.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169080,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q4fy25-28-rise-in-profits\/","url_meta":{"origin":180789,"position":1},"title":"ERIS Lifesciences Ltd Q4FY25; 28% rise in Profits","author":"Divyansh_Kasana","date":"July 10, 2025","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q4FY25 of \u20b9705.00 Crores up from \u20b9551.00 Crore year on year, a rise of 27.95%. Total Expenses for Q4FY25 of \u20b9584.00 Crores up from \u20b9489.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167647,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q3fy25-14-fall-in-profits\/","url_meta":{"origin":180789,"position":2},"title":"ERIS Lifesciences Ltd Q3FY25; 14% fall in Profits","author":"Divyansh_Kasana","date":"March 31, 2025","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q3FY25 of \u20b9727.00 Crores up from \u20b9486.00 Crore year on year, a rise of 49.59%. Total Expenses for Q3FY25 of \u20b9615.00 Crores up from \u20b9375.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/L-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151417,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q1fy24-1-rise-in-profits\/","url_meta":{"origin":180789,"position":3},"title":"ERIS Lifesciences Ltd Q1FY24; 1% rise in Profits","author":"Hardik Bhandare","date":"August 7, 2023","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q1FY24 of \u20b9467.00 Crores up from \u20b9399.00 Crore year on year, a rise of 17.04%. Total Expenses for Q1FY24 of \u20b9355.00 Crores up from \u20b9299.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-246.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162460,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q4fy24-31-rise-in-profits\/","url_meta":{"origin":180789,"position":4},"title":"ERIS Lifesciences Ltd Q4FY24; 31% rise in Profits","author":"Divyansh_Kasana","date":"June 24, 2024","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q4FY24 of \u20b9551.00 Crores up from \u20b9403.00 Crore year on year, a rise of 36.72%. Total Expenses for Q4FY24 of \u20b9489.00 Crores up from \u20b9328.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-205.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":159968,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q3fy24-1-rise-in-profits\/","url_meta":{"origin":180789,"position":5},"title":"ERIS Lifesciences Ltd Q3FY24; 1% rise in Profits","author":"Divyansh_Kasana","date":"March 18, 2024","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q3FY24 of \u20b9486.00 Crores up from \u20b9423.00 Crore year on year, a rise of 14.89%. Total Expenses for Q3FY24 of \u20b9375.00 Crores up from \u20b9319.00 Crores year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/03\/image-185.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2400"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180789"}],"version-history":[{"count":4,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180789\/revisions"}],"predecessor-version":[{"id":180797,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180789\/revisions\/180797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}